Abstract

Objective Human colorectal cancer (CRC) is the third most common cancer; patients with metastatic colorectal cancer (mCRC) show poor prognosis than those with CRC cases. There are no reliable molecular biomarkers for the diagnosis of CRC prognosis except with pathological features. Therefore, it is urgent to develop a biomarker for diagnosis and/or prediction of human CRC. In addition, capping actin protein (CapG) belongs to the gelsolin family and has been reported to contribute on tumor invasion/metastasis in multiple human cancers. Here, we are the first to evaluate the expression of CapG in human CRCs. Study Design To investigate the expression levels of CapG in human tissue array by immunohistochemistry (IHC) staining. Moreover, the mRNA and protein levels were also confirmed in four CRC cell lines and determined using real-time RT-PCR and Western blotting. Finally, a Matrigel transwell invasion assay was used to evaluate the invasion ability in CapG high or low expression cells. Results We demonstrated that CapG could be determined in the normal colon tissue and human CRC specimens. However, CapG was significantly overexpressed in the mCRC specimens compared with that in CRC specimens and normal cases. It was also detectable in the four CRC cell lines including mRNA and protein levels. We also found that knockdown of the expression of CapG reduced tumor migration. Conclusions In this study, we suggested that CapG could be used as a biomarker for metastatic CRC in the clinical specimens. Moreover, our in vitro study demonstrated that CapG might contribute on tumor metastasis in human CRCs.

Highlights

  • Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer-related death in men and women worldwide

  • The expression of capping actin protein (CapG) in the CRC clinical specimens including 9 normal cases, 39 CRC cases, and 9 metastatic CRC cases was validated by IHC staining and determined under microscopy (Supplementary data 1)

  • We demonstrated that CapG could be determined in the normal colon tissue and human CRC specimens

Read more

Summary

Introduction

Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer-related death in men and women worldwide. Current clinical treatment strategy for CRC includes surgical resection, chemotherapy, and target therapies. The prognosis of patients with CRC is determined by pathological features and the diagnostic stage of the tumor. In patients with in situ carcinoma of CRC, the 5-year survival rate is. Patients with metastatic colorectal cancer (mCRC) have poor prognosis, and the five-year survival rate is 10–20% [2]. The target therapies including monoclonal antibodies against receptor tyrosine kinases (RTK) such as epidermal growth factor receptor (EGFR) may contribute to the improvement in survival of mCRC patients. Early diagnosis for CRC patients or identification of predictive markers for treatment of mCRC patients is urgent

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call